GeoVax Labs (GOVX -6.33%), a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer, reported its second quarter 2025 results on July 28, 2025. The company posted GAAP revenue ahead of expectations, and continued to advance its lead clinical programs but highlighted increased operating costs and tightening cash reserves. GAAP revenue rose to $0.85 million, well above the analyst estimate of $0.39 million, while GAAP earnings per share came ...